- Home
- OPK vs ARQT Comparison
OPK vs ARQT Comparison
Compare OPK & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- ARQT
- Stock Information
- Founded
- OPK 2007
- ARQT 2016
- Country
- OPK United States
- ARQT United States
- Employees
- OPK N/A
- ARQT N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- ARQT Health Care
- Exchange
- OPK Nasdaq
- ARQT Nasdaq
- Market Cap
- OPK N/A
- ARQT 1.7B
- IPO Year
- OPK 1995
- ARQT 2020
- Fundamental
- Price
- OPK $1.35
- ARQT $15.00
- Analyst Decision
- OPK Buy
- ARQT Strong Buy
- Analyst Count
- OPK 4
- ARQT 6
- Target Price
- OPK $2.75
- ARQT $18.80
- AVG Volume (30 Days)
- OPK 3.4M
- ARQT 2.0M
- Earning Date
- OPK 08-06-2025
- ARQT 08-13-2025
- Dividend Yield
- OPK N/A
- ARQT N/A
- EPS Growth
- OPK N/A
- ARQT N/A
- EPS
- OPK N/A
- ARQT N/A
- Revenue
- OPK $689,408,000.00
- ARQT $212,819,000.00
- Revenue This Year
- OPK N/A
- ARQT $61.15
- Revenue Next Year
- OPK $7.80
- ARQT $37.98
- P/E Ratio
- OPK N/A
- ARQT N/A
- Revenue Growth
- OPK N/A
- ARQT 100.03
- 52 Week Low
- OPK $1.21
- ARQT $7.86
- 52 Week High
- OPK $2.04
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- OPK 52.54
- ARQT 60.23
- Support Level
- OPK $1.33
- ARQT $13.06
- Resistance Level
- OPK $1.36
- ARQT $15.36
- Average True Range (ATR)
- OPK 0.04
- ARQT 0.66
- MACD
- OPK 0.01
- ARQT 0.12
- Stochastic Oscillator
- OPK 73.33
- ARQT 82.57
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.